Dong-A ST

Dong-A ST is a leading South Korean pharmaceutical and biotech company with a strong focus on small molecule drugs, biosimilars, and biologics. The company has several approved products in major indications such as diabetes, erectile dysfunction, prostatic hyperplasia, growth disorders, and bacterial infections. It invests heavily in R&D and is expanding into oncology and immune disease therapeutics through partnerships. Its pipeline includes both proprietary novel drugs and biosimilars; key marketed products include Evogliptin Tartrate for diabetes, Udenafil for erectile dysfunction, Naftopidil for prostatic hyperplasia, Somatropin biosimilar for growth disorders in children, and Tedizolid Phosphate for bacterial infections[1][4][5][8].